|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sano D and Myers JN: Metastasis of
squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev.
26:645–662. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Neville BW and Day TA: Oral cancer and
precancerous lesions. CA Cancer J Clin. 52:195–215. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ren W, Lian P, Cheng L, Du P, Guan X, Wang
H, Ding L, Gao Z, Huang X, Xiao F, et al: FHL1 inhibits the growth
of tongue squamous cell carcinoma cells via G1/S cell cycle arrest.
Mol Med Rep. 12:3958–3964. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Z, He Q, Ding X, Zhao T, Zhao L and
Wang A: SOD2 is a C-myc target gene that promotes the migration and
invasion of tongue squamous cell carcinoma involving cancer
stem-like cells. Int J Biochem Cell Biol. 60:139–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jia LF, Gan YH and Yu GY: Relationships
between microRNA expressions and prognosis in patients with tongue
squamous cell carcinoma and the mechanisms microRNA regulating
tongue squamous cell carcinoma biological behavior. Beijing Da Xue
Xue Bao Yi Xue Ban. 48:5–9. 2016.(In Chinese). PubMed/NCBI
|
|
8
|
Hotta H, Ross AH, Huebner K, Isobe M,
Wendeborn S, Chao MV, Ricciardi RP, Tsujimoto Y, Croce CM and
Koprowski H: Molecular cloning and characterization of an antigen
associated with early stages of melanoma tumor progression. Cancer
Res. 48:2955–2962. 1988.PubMed/NCBI
|
|
9
|
Maecker HT, Todd SC and Levy S: The
tetraspanin superfamily: Molecular facilitators. FASEB J.
11:428–442. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pols MS and Klumperman J: Trafficking and
function of the tetraspaninCD63. Exp Cell Res. 315:1584–1592. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kobayashi T, Vischer UM, Rosnoblet C,
Lebrand C, Lindsay M, Parton RG, Kruithof EK and Gruenberg J: The
tetraspanin CD63/lamp3 cycles between endocytic and secretory
compartments in human endothelial cells. Mol Biol Cell.
11:1829–1843. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang M, Ryu J, Lee D, Lee MS, Kim HJ, Nam
SH, Song HE, Choi J, Lee GH, Kim TY, et al: Correlations between
transmembrane 4 L6 family member 5 (TM4SF5), CD151, and CD63 in
liver fibrotic phenotypes and hepatic migration and invasive
capacities. PLoS One. 9:e1028172014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hunziker W and Geuze HJ: Intracellular
trafficking of lysosomal membrane proteins. Bioessays. 18:379–389.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Atkinson B, Ernst CS, Ghrist BF, Herlyn M,
Blaszczyk M, Ross AH, Herlyn D, Steplewski Z and Koprowski H:
Identification of melanoma-associated antigens using fixed tissue
screening of antibodies. Cancer Res. 44:2577–2581. 1984.PubMed/NCBI
|
|
15
|
Jang HI and Lee H: A decrease in the
expression of CD63 tetraspanin protein elevates invasive potential
of human melanoma cells. Exp Mol Med. 35:317–323. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Radford KJ, Thorne RF and Hersey P:
Regulation of tumor cell motility and migration by CD63 in a human
melanoma cell line. J Immunol. 158:3353–3358. 1997.PubMed/NCBI
|
|
17
|
Kwon MS, Shin SH, Yim SH, Lee KY, Kang HM,
Kim TM and Chung YJ: CD63 as a biomarker for predicting the
clinical outcomes in adenocarcinoma of lung. Lung Cancer. 57:46–53.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sauer G, Kurzeder C, Grundmann R,
Kreienberg R, Zeillinger R and Deissler H: Expression of
tetraspanin adaptor proteins below defined threshold values is
associated with in vitro invasiveness of mammary carcinoma
cells. Oncol Rep. 10:405–410. 2003.PubMed/NCBI
|
|
19
|
Sordat I, Decraene C, Silvestre T,
Petermann O, Auffray C, Piétu G and Sordat B: Complementary DNA
arrays identify CD63 tetraspanin and alpha3 integrin chain as
differentially expressed in low and high metastatic human colon
carcinoma cells. Lab Invest. 82:1715–1724. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shear M: The aggressive nature of the
odontogenic keratocyst: Is it a benign cystic neoplasm? Part 3.
Immunocytochemistry of cytokeratin and other epithelial cell
markers. Oral Oncol. 38:407–415. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Woegerbauer M, Thurnher D, Houben R,
Pammer J, Kloimstein P, Heiduschka G, Petzelbauer P and Erovic BM:
Expression of the tetraspanins CD9, CD37, CD63, and CD151 in Merkel
cell carcinoma: Strong evidence for a posttranscriptional
fine-tuning of CD9 gene expression. Mod Pathol. 23:751–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Z, Gu S, Trojanowicz B, Liu N, Zhu G,
Dralle H and Hoang-Vu C: Down-regulation of TM4SF is associated
with the metastatic potential of gastric carcinoma TM4SF members in
gastric carcinoma. World J Surg Oncol. 9:432011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fellmann C and Lowe SW: Stable RNA
interference rules for silencing. Nat Cell Biol. 16:10–18. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stepanenko AA and Dmitrenko VV: HEK293 in
cell biology and cancer research: Phenotype, karyotype,
tumorigenicity, and stress-induced genome-phenotype evolution.
Gene. 569:182–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: Biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yurchenco PD and Schittny JC: Molecular
architecture of basement membranes. FASEB J. 4:1577–1590. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barsky SH, Siegal GP, Jannotta F and
Liotta LA: Loss of basement membrane components by invasive tumors
but not by their benign counterparts. Lab Invest. 49:140–147.
1983.PubMed/NCBI
|
|
29
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kusukawa J, Sasaguri Y, Shima I, Kameyama
T and Morimatsu M: Expression of matrix metalloproteinase-2 related
to lymph node metastasis of oral squamous cell carcinoma. A
clinicopathologic study. Am J Clin Pathol. 99:18–23. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kawamata H, Uchida D, Hamano H,
Kimura-Yanagawa T, Nakashiro KI, Hino S, Omotehara F, Yoshida H and
Sato M: Active-MMP2 in cancer cell nests of oral cancer patients:
Correlation with lymph node metastasis. Int J Oncol. 13:699–704.
1998.PubMed/NCBI
|
|
32
|
Ikebe T, Shinohara M, Takeuchi H, Beppu M,
Kurahara S, Nakamura S and Shirasuna K: Gelatinolytic activity of
matrix metalloproteinase in tumor tissues correlates with the
invasiveness of oral cancer. Clin Exp Metastasis. 17:315–323. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hong SD, Hong SP, Lee JI and Lim CY:
Expression of matrix metalloproteinase-2 and −9 in oral squamous
cell carcinomas with regard to the metastatic potential. Oral
Oncol. 36:207–213. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yorioka CW, Coletta RD, Alves F, Nishimoto
IN, Kowalski LP and Graner E: Matrix metalloproteinase-2 and −9
activities correlate with the disease-free survival of oral
squamous cell carcinoma patients. Int J Oncol. 20:189–194.
2002.PubMed/NCBI
|
